- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04910438
Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo. (DepIST-H)
Prevalence and Longitudinal Follow-up Over 2 Years of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men (MSM) in Lomé, Togo
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Title: Prevalence and longitudinal follow-up over 2 years of anal lesions, HPV infection and associated sexually transmitted infections among men who have sex with men (MSM) in Lomé, Togo (ANRS12400 DepIST-H)
Main objective: To estimate the prevalence and incidence of anal lesions (condyloma, dysplasia and anal cancers) according to HIV status among MSM in Lomé, Togo
Specific objectives :
To estimate the prevalence of HPV infection at baseline (M0) at anal and oropharyngeal sites To describe the persistence of HPV infection at Year 1 and 2 at the anal and oropharyngeal sites To describe the recurrence of anal lesions at Year 1 and 2 To estimate prevalence and incidence of associated STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex Virus type 2, Mycoplasma genitalium, Trichomonas vaginalis) HBV, HCV and syphilis
Methods :
This study is a prospective cohort with a 2-year follow-up of 200 MSM in Lomé (100 HIV- and 100 HIV+). Three data collection systems are integrated into the cohort: (i) clinical data, (ii) socio-behavioural questionnaires, and (iii) biological data.
Sample size: 200 participants (100 HIV+ and 100 HIV-)
Interventions :
Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).
Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM.
Statistical analysis methods :
Use of mixed approaches. For quantitative indicators, descriptive analysis techniques, bivariate analysis (Student t test or Wilcoxon test for quantitative variables, Chi² or Fisher test for categorical variables) and multivariate analysis (logistic regression).
To estimate the incidence if the STIs, Kaplan-Meier curves, Cox models analyses will be conducted.
As the cohort is open and non-randomized, preliminary analyses will be conducted during the collection.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Didier Koumavi Ekouevi
- Phone Number: +228 99 68 67 35
- Email: didier.ekouevi@gmail.com
Study Contact Backup
- Name: Arnold Sadio
- Email: sadioarnold@gmail.com
Study Locations
-
-
-
Lomé, Togo
- Recruiting
- ONG, Espoir Vie Togo
-
Contact:
- Ephrem Mensah, MD
- Phone Number: +228 90 01 64 11
- Email: ephremensah@hotmail.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Being a male aged 18 or over
- Self-reporting as being a MSM
- Wishing to be part of a regular clinical follow-up
- Agreeing to participate in the study and signing the informed consent form
- Live in Lomé
- Having had anal intercourse within the past six months prior to inclusion visit
- Regardless of HIV status (infected or not)
- Whether or not the participant has already taken antiretrovirals
Exclusion Criteria:
- Participation in another biomedical and/or behavioural study on HIV, viral hepatitis or sexually transmitted infections (CohMSM ANRS 12324-EF cohort of Lomé)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence at inclusion of anal lesions
Time Frame: at Day 0
|
According to HIV status among MSM in Lomé, Togo
|
at Day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of anal lesions at baseline
Time Frame: at Day 0
|
According to HIV status among MSM in Lomé, Togo
|
at Day 0
|
Incidence of anal lesions
Time Frame: at 12 month and 24 month
|
According to HIV status among MSM in Lomé, Togo
|
at 12 month and 24 month
|
Describe the number of worsening events of anal cytological lesions
Time Frame: at 12 month and 24 month
|
According to HIV status among MSM in Lomé, Togo
|
at 12 month and 24 month
|
Describe the proportion of recurrence of anal lesions
Time Frame: at 12 month and 24 month
|
According to HIV status among MSM who received available treatment, in Lomé, Togo
|
at 12 month and 24 month
|
Prevalence of HPV infections
Time Frame: at Day 0
|
at Day 0
|
|
Incidence of HPV infection
Time Frame: at 12 month and 24 month
|
at 12 month and 24 month
|
|
Describe the proportion of persistent HPV infections
Time Frame: at 12 month and 24 month
|
at 12 month and 24 month
|
|
Describe the proportion of clearance of HPV infections
Time Frame: at 12 month and 24 month
|
in the same individual, on anal and oral specimens, based on HIV status.
|
at 12 month and 24 month
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of others STIs : N. gonorrhoeae, C. trachomatis, M. genitalium, T. vaginalis, Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C
Time Frame: At Day 0, at 12 month and 24 month
|
According to HIV status
|
At Day 0, at 12 month and 24 month
|
Incidence of others STIs : Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis and Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C
Time Frame: At Day 0, at 12 month and 24 month
|
According to HIV status
|
At Day 0, at 12 month and 24 month
|
Determination of different Chlamydia trachomatis strains
Time Frame: At Day 0
|
At Day 0
|
|
Determination of antibiotic resistance profiles for Neisseria gonorrhoeae, Mycoplasma genitalium and Chlamydia trachomatis
Time Frame: At Day 0
|
According to HIV status
|
At Day 0
|
Incidence of HIV
Time Frame: at 12 month and 24 month
|
at 12 month and 24 month
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Charlotte Charpentier, Hôpital Bichat Claude Bernard, Paris, France
- Principal Investigator: Didier Ekouevi, Lomé University, Togo
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANRS 12400 DepIST-H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on STIs screening and care
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and... and other collaboratorsCompletedHIV InfectionsUnited States
-
University of North Carolina, Chapel HillCenters for Disease Control and PreventionCompletedHIV InfectionsUnited States
-
Clinical Directors NetworkCompletedDepression | Cervical Cancer Screening | Breast Cancer Screening | Colorectal Cancer ScreeningUnited States
-
University at AlbanyJohns Hopkins UniversityCompletedDomestic Violence
-
University of ManitobaAlberta Health services; Research Manitoba; Canadians Seeking Solutions and Innovations... and other collaboratorsRecruitingHypertension | Diabetes | Chronic Kidney DiseaseCanada
-
University of Texas Southwestern Medical CenterCancer Prevention Research Institute of Texas; Parkland Health and Hospital...CompletedColorectal CancerUnited States
-
Indiana UniversityIndiana Clinical and Translational Sciences Institute; Purdue University; Moi...CompletedDiabetes, Gestational
-
Olmsted Medical CenterUnknownPostpartum DepressionUnited States
-
Changi General HospitalNational University Hospital, SingaporeCompleted
-
University of La LagunaCompletedHepatitis C Virus InfectionSpain